2026 Guide: Medicare & NYRx Medicaid CGM Coverage
Understanding the evolving 2026 insurance landscape is the first step to securing your Continuous Glucose Monitor. Palma Care DME specializes in navigating NYRx Medicaid and Medicare Part B requirements to ensure eligible New York residents receive their Dexcom G7 or FreeStyle Libre 3 Plus with $0 out-of-pocket costs.
In 2026, NYRx continues to prioritize "Preferred" devices for streamlined approval.
-
Preferred Devices: Dexcom G7 and FreeStyle Libre 3 Plus.
-
Eligibility: Requires a diagnosis of Diabetes Mellitus (Type 1 or Type 2) and a documented need for frequent glucose monitoring.
-
The "Palma" Process: We verify your NYRx status instantly and coordinate with your OB-GYN or Endocrinologist to secure the necessary electronic prescription via Parachute Health.
NYRx Medicaid: Preferred Diabetic Supply Program (PDSP)
Medicare guidelines have expanded in 2026 to include a broader range of Type 2 patients. To qualify for a covered CGM, the following clinical documentation is required:
-
Insulin Treatment: Use of any insulin regimen (pump or injections).
-
OR Problematic Hypoglycemia: Documentation of recurrent Level 2 lows (below 54mg/dL) or a single Level 3 event requiring third-party assistance.
-
Clinical Evaluation: A face-to-face or telehealth visit with your prescriber within the last 6 months specifically discussing your diabetes management.
FDA-Cleared Placement Sites
Maintaining Your Long-Term Eligibility
A common "hiccup" for patients is losing coverage after the first 6 months. To ensure uninterrupted supply delivery:
-
Follow-up Visits: Medicare requires a follow-up clinical evaluation every 6 months to document that the CGM is improving your glycemic control.
-
Competency Training: Your doctor must document that you (or a caregiver) have been trained to use the device. Palma Care DME provides the training resources to support this requirement.




